Table 4.
Clinical-pathological findings, treatment and follow-up of the study population, n = 88
|
|
MCL, n = 40
|
HR, n = 20
|
NLOD, n = 20
|
CG, n = 8
|
Total, n = 88
|
| PA in EUS | |||||
| No | 0 (0.0) | 18 (90.0) | 13 (65.0) | 8 (100.0) | 39 (44.3) |
| Yes | 40 (100.0) | 2 (10.0) | 7 (35.0) | 0 (0.0) | 49 (55.7) |
| Type of PA | |||||
| Cystic lesions | 40 (100.0) | 2 (100.0) | 2 (28.6) | - | 44 (89.8) |
| CP-like parenchymal changes | 0 (0.0) | 0 (0.0) | 2 (28.6) | - | 2 (4.1) |
| Solid lesions | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) |
| Lipomatous transformation | 0 (0.0) | 0 (0.0) | 3 (42.8) | - | 3 (6.1) |
| PA with HRS / WF | |||||
| No | 20 (50.0) | 2 (100.0) | 7 (100.0) | - | 29 (59.2) |
| Yes | 20 (50.0) | 0 (0.0) | 0 (0.0) | - | 20 (40.8) |
| EUS FNA/B | |||||
| No | 5 (12.5) | 20 (100.0) | 20 (100) | 8 (100) | 53 (60.2) |
| Yes | 35 (87.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 35 (39.8) |
| Inconclusive | 13 (37.1) | - | - | - | 13 (37.1) |
| Benign | 19 (54.3) | - | - | - | 19 (54.3) |
| Malignant | 3 (8.6)1 | - | - | - | 3 (8.6)1 |
| Surgery | |||||
| No | 25 (62.5) | 20 (100) | 20 (100) | 8 (100) | 73 (83.0) |
| Yes | 15 (37.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 15 (17.0) |
| Benign/Malignant | 12 (80.0)/3 (20.0) | -/- | -/- | -/- | 12 (80.0)/3 (20.0) |
| F-up in mo | 33.3 ± 12.8 | 34.9 ± 7.1 | 27.7 ± 4.7 | 36.1 ± 5.1 | 32.6 ± 10.0 |
| Cancer detection during F-up | 1 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) |
| Mortality | 5 (12.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (5.7) |
Data are presented as n (%) or mean ± SD.
1
One of 3 patients with malignant cytology was diagnosed during follow-up.
CG: Control group; CP: Chronic pancreatitis; EUS: Endoscopic ultrasound; FNA/B: Fine needle aspiration/biopsy; F-up: Follow up; HR: Hereditary risk; HRS: High risk stigmata; MCL: Mucinous cystic lesion; NLOD: New-late onset diabetes mellitus; NS: Non-significant; PA: Pancreatic abnormality; WF: Worrisome features.